CLAIMS

1. Use of a tocilizumab in the manufacture of a medicament for treating rheumatoid arthritis, wherein said tocilizumab is to be administered to a subject at a starting dose of:

a. 162 mg of tocilizumab once per week subcutaneously; or

b. 8 mg/kg of tocilizumab once every 4 weeks intravenously, and wherein:

(A) the subject to be administered the starting dose has not previously been administered with tocilizumab or who has been administered with tocilizumab for less than three months at a dose that is lower than the starting dose, and

(B) the subject, prior to the starting dose to be administered, is determined that the subject does not have anemia.

2. Use of a tocilizumab in the manufacture of a medicament for treating rheumatoid arthritis, wherein said tocilizumab is to be administered to a subject at a starting dose of:

a. 162 mg of tocilizumab once per week subcutaneously; or

b. 8 mg/kg of tocilizumab once every 4 weeks intravenously, and wherein:

(A) the subject to be administered the starting dose has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months at a dose that is lower than the starting dose, and

(B) the subject, prior to the starting dose to be administered, is determined that the subject is from 18 to 34 years old.

3. Use of a tocilizumab in the manufacture of a medicament for treating rheumatoid arthritis, wherein said tocilizumab is to be administered to a subject at a starting dose of:

a. 162 mg of tocilizumab once per week subcutaneously; or

b. 8 mg/kg of tocilizumab once every 4 weeks intravenously, and wherein:

(A) the subject to be administered the starting dose has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months at a dose that is lower than the starting dose, and

(B) the subject, prior to the starting dose to be administered, is determined that the subject has not been administered with a corticosteroid within 90 days of the starting dose.

4. Use of a tocilizumab in the manufacture of a medicament for treating rheumatoid arthritis, wherein said tocilizumab is to be administered to a subject at a starting dose of:

a. 162 mg of tocilizumab once per week subcutaneously; or

b. 8 mg/kg of tocilizumab once every 4 weeks intravenously, and wherein:

(A) the subject to be administered the starting dose has not previously been administered with tocilizumab or has been administered with tocilizumab for less than three months at a dose that is lower than the starting dose, and

(B) the subject, prior to the starting dose to be administered, is determined that the subject has depression.

5. The use of any one of claims 1-4, wherein the subject to be administered the starting dose has moderately-to-severely active rheumatoid arthritis.

6. The use of any one of claims 1-5, wherein the subject to be administered the starting dose has not previously been administered sarilumab.

7. The use of any one of claims 1-6, wherein the subject to be administered the starting dose weighs less than 100 kg.

8. The use of any one of claims 1-7, wherein the subject to be administered the starting dose does not have ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, ulcerative colitis, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, or giant-cell arteritis.

9. The use of any one of claims 1, and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject does not have anemia and is from 18 to 34 years old.

10. The use of any one of claims 1, and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject does not have anemia and has not been administered a corticosteroid within 90 days of the starting dose.

11. The use of any one of claims 2, and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject is from 18 to 34 years old and has not been administered a corticosteroid within 90 days of the starting dose.

12. The use of any one of claims 1 and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject does not have anemia, has not been administered a corticosteroid within 90 days of the starting dose, and is from 18 to 34 years old.

13. The use of any one of claims 1 and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject does not have anemia and has depression.

14. The use of any one of claims 3 and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject has depression and has not been administered a corticosteroid within 90 days. of the starting dose.

15. The use of any one of claims 2 and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject is from 18 to 34 years old and has depression.

16. The use of any one of claims 1, and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject does not have anemia, has depression and is from 18 to 34 years old.

17. The use of any one of claims 1 and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject does not have anemia, has depression, and has not been administered a corticosteroid within 90 days of the starting dose.

18. The use of any one of claims 2 and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject is from 18 to 34 years old, has depression, and has not been administered a corticosteroid within 90 days of the starting dose.

19. The use of any one of claims 1 and 5-8, wherein the subject, prior to the starting dose to be administered, is determined that the subject does not have anemia, has not been administered a corticosteroid within 90 days, is from 18 to 34 years old, and has depression.

20. The use of any one of claims 3, 10-12, 14, and 17-18, wherein the corticosteroid is prednisone.

21. The use of any one of claims 1-20, wherein tocilizumab of the medicament is not to be administered with any other disease-modifying antirheumatic drug (DMARD).

22. The use of any one of claims 1-20, wherein tocilizumab of the medicament is to be administered with one or more additional DMARDs.

23. The use of claim 22, wherein the one or more additional DMARDs comprise methotrexate.

24. The use of any one of claims 1-23, wherein the subject to be administered the starting dose previously had an inadequate response to a DMARD.

25. The use of claim 24, wherein the DMARD is a synthetic DMARD, which comprises methotrexate.

26. The use of claim 24, wherein the DMARD is a biologic DMARD, which comprises a tumor necrosis factor alpha (TNF-α) inhibitor.

27. The use of claim 26, wherein the TNF-α inhibitor comprises adalimumab.

28. The use of any one of claims 1-27, wherein the subject to be administered the starting dose has not previously been administered with tocilizumab.

29. The use of any one of claims 1-27, wherein the subject to be administered the starting dose has been administered with tocilizumab for less than three months at a dose that is lower than the starting dose.

30. The use of any one of claims 1-27, wherein the subject to be administered the starting dose has been administered with tocilizumab for less than two months at a dose that is lower than the starting dose.

31. The use of any one of claims 1-27, wherein the subject to be administered the starting dose has been administered with tocilizumab for less than one month at a dose that is lower than the starting dose.

32. The use of any one of claims 1-31, wherein the subject to be administered the starting dose is female.